Difference in time-course of improvement in asthma control measures between budesonide and budesonide/formoterol

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 189-194

  Matsunaga, Kazuto ^a   Kawabata, Hiroki ^a   Hirano, Tsunahiko ^a   Sugiura, Hisatoshi ^a   Minakata, Yoshiaki ^a   Ichinose, Masakazu ^b  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ACQ; AHR; Airflow limitation; Airway hyperresponsiveness; Airway inflammation; Asthma Control Questionnaire; BUD; Exhaled nitric oxide; FENO; FM; PD200

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; METHACHOLINE; NITRIC OXIDE;

ADULT; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DOSE TIME EFFECT RELATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG RESISTANCE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; BREATH TESTS; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; NITRIC OXIDE; PROSPECTIVE STUDIES;

EID: 84874569314     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.10.006     Document Type: Article

References (26)

1. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achived? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004, 170:836-844.
2. Barnes N.C., Jacques L., Goldfrad C., Bateman ED. Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100μg bd versus fluticasone propionate 100μg bd alone in patients with persistent asthma: integrated analysis of four randomised trials. Respir Med 2007, 101:2358-2365.
3. Renzi P.M., Howard L.A., Ortega H.G., Ahmad F.F., Chapman K.R. Low-dose fluticasone propionate in steroid-naive patients with mild, uncontrolled asthma. Respir Med 2010, 104:510-517.
4. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstorm T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001, 164:1392-1397.
5. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations. Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99.
6. Bates C.A., Silkoff P.E. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003, 111:256-262.
7. Reddel H.K., Jenkins C.R., Marks G.B., Ware S.I., Xuan W., Salome C.M., et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000, 16:226-235.
8. Reddel H.K., Marks G.B., Jenkins C.R. When can personal best peak flow be determined for asthma action plan?. Thorax 2004, 59:922-924.
9. Global initiative for asthma. Updated 2008. http://www.ginaasthma.%20com/Guidelineitem.asp%3f%3f11%3d2%2612%3d1%26intld%3d60.
10. Juniper E.F., Bousquet J., Abetz L., Bateman E.D. Identifying 'well-controlled' and 'not well-controlled' asthma using the asthma control questionnaire. Respir Med 2006, 100:616-621.
11. Matsunaga K., Hirano T., Akamatsu K., Koarai A., Sugiura H., Minakata Y., et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int 2011, 60:331-337.
12. Takishima T., Hida W., Sasaki H., Suzuki S., Sasaki T. Direct writing recorder of the dose-response curves of the airway to methacholine. Chest 1981, 80:600-606.
13. Matsunaga K., Yanagisawa S., Ichikawa T., Ueshima K., Akamatsu K., Hirano T., et al. Airway cytokine expression measured by means of protein array in exhaled breath condensate: correlation with physiologic properties in asthmatic patients. J Allergy Clin Immunol 2006, 118:84-90.
14. Juniper E.F., Svensson K., Mork A.C., Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005, 99:553-558.
15. Matsunaga K., Hirano T., Kawayama T., Tsuburai T., Nagase H., Aizawa H., et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int 2010, 59:363-367.
16. Walsh L.J., Wong C.A., Oborne J., Cooper S., Lewis S.A., Pringle M., et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001, 56:279-284.
17. Massaro A.F., Gaston B., Kita D., Fanta C., Stamler J.S., Drazen J.M. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995, 152:800-803.
18. Delean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978, 235:97-102.
19. Golan D.E., Tashjian A.H., Armstrong E.J., Armstrong A.W. Principles of pharmacology: the pathophysiologic basis of drug therapy 2011, Lippincott Williams & Wilkins, Baltimore, p. 17-26. 3rd ed.
20. Leuppi J.D., Salome C.M., Jenkins C.R., Anderson S.D., Xuan W., Marks G.B., et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001, 163:406-412.
21. Salome C.M., Leuppi J.D., Freed R., Marks G.B. Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation. Thorax 2003, 58:1042-1047.
22. Sont J.K., Willems L.N., Bel E.H., van Krieken J.H., Vandenbroucke J.P., Sterk PJ. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999, 159:1043-1051.
23. Ichinose M., Takahashi H., Sugiura N., Endoh N., Miura M., Mashito Y., et al. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway caliber. Eur Respir J 2000, 15:248-253.
24. Matsunaga K., Kanda M., Hayata A., Yanagisawa S., Ichikawa T., Akamatsu K., et al. Peak expiratory flow variability adjusted by forced expiratory volume in one second is a good index for airway responsiveness in asthmatics. Intern Med 2008, 47:1107-1112.
25. Gelb A.F., Flynn Taylor C., Shinar C.M., Gutierrez C., Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006, 129:1492-1499.
26. Lundback B., Ronmark E., Lindberg A., Jonsson A.C., Larsson L.G., James M. Asthma control over 3 years in a real-life study. Respir Med 2009, 103:348-355.